With Trump's tariffs looming, is this really the appropriate time to load up on pharma stocks? And where does Cipla stand in ...

NEW DELHI: Indian Pharmaceutical company Cipla has offered to manufacture an ... The patent for Tamiflu is pending in India and the government is yet to decide on how to make the drug in the ...

Pharma major Cipla Ltd on Tuesday posted its highest-ever quarterly revenue and Ebitda margin, as robust sales in India, Europe and ... is being filed from its US plant, the launch timeline ...

This combination drug, that was previously available only in the U.S. and European countries, was first launched in India by Cipla on Thursday. In the U.S. and Europe this combination drug costs Rs.

New Delhi, Feb 8 () Homegrown pharma firm Cipla on Saturday announced the acquisition ... by Wanbury have a market size of Rs 3,100 crore in India with sales value of Rs 59.6 crore.

Nomura India maintains 'Buy' rating on Cipla with Rs 1,780 target by March 2026. Cipla's Goa site receives USFDA approval for gAbraxane, paving way for FY26 launch. Launch expected in 1HFY26 ...